公开(公告)号：US6083993A

公开(公告)日：2000-07-04

申请号：US466107

申请日：1999-12-17

Applicant: Timothy J. Barberich ,  James W. Young

Inventor： Timothy J. Barberich ,  James W. Young

IPC: A61K31/135 ,  A61K31/165 ,  A61K31/19 ,  A61K31/60 ,  A61K31/616 ,  A61P11/00 ,  A61P11/08

CPC classification number: A61K31/135

Abstract: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.

Abstract translation: 基本上不含S（+）异构体的沙丁胺醇的光学纯的R（ - ）异构体是一种有效的支气管扩张剂，用于缓解个体与哮喘相关的症状。 公开了利用沙丁胺醇的光学纯的R（ - ）异构体治疗哮喘，同时最小化与沙丁胺醇相关的副作用的方法。

公开(公告)号：US5708035A

公开(公告)日：1998-01-13

申请号：US446348

申请日：1995-05-22

Applicant: James W. Young ,  Timothy J. Barberich ,  Martin H. Teicher

Inventor： James W. Young ,  Timothy J. Barberich ,  Martin H. Teicher

IPC: A61K31/138 ,  A61K31/35

CPC classification number: A61K31/138

Abstract: A method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of adverse effects. In addition, a method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is useful to treat migraine headaches, pain, in particular chronic pain, psychoactive substance abuse disorders and obsessive compulsive disorders.

Abstract translation: 公开了使用氟西汀的纯R（ - ）异构体的方法和组合物，其是有效的抗抑郁药和食欲抑制剂，其基本上没有不利影响。 另外，公开了使用氟西汀的纯R（ - ）异构体的方法和组合物，其可用于治疗偏头痛，疼痛，特别是慢性疼痛，精神活性物质滥用障碍和强迫症。

公开(公告)号：US5547994A

公开(公告)日：1996-08-20

申请号：US335480

申请日：1994-11-07

Applicant: Timothy J. Barberich ,  James W. Young

Inventor： Timothy J. Barberich ,  James W. Young

IPC: A61K31/135 ,  A61K31/137

CPC classification number: A61K31/137 ,  A61K31/135 ,  Y10S514/826

Abstract: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.

Abstract translation: 基本上不含S（+）异构体的沙丁胺醇的光学纯的R（ - ）异构体是一种有效的支气管扩张剂，用于缓解个体与哮喘相关的症状。 公开了利用沙丁胺醇的光学纯的R（ - ）异构体治疗哮喘，同时最小化与沙丁胺醇相关的副作用的方法。

公开(公告)号：US08097625B2

公开(公告)日：2012-01-17

申请号：US11761235

申请日：2007-06-11

Applicant: Karim Lalji ,  Timothy J. Barberich ,  Judy Caron ,  Thomas Wessel

Inventor： Karim Lalji ,  Timothy J. Barberich ,  Judy Caron ,  Thomas Wessel

IPC: A01N43/58 ,  A01N43/40 ,  A61K31/50 ,  A61K31/497 ,  A61K31/435

CPC classification number: A61K31/4985 ,  A61K31/137 ,  A61K31/138 ,  A61K31/495 ,  A61K31/724 ,  A61K45/06 ,  A61K2300/00

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.

Abstract translation: 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，当它们一起被用于治疗，例如失眠和/或抑郁症时。 药物组合物的第一组分是调节GABA受体的化合物。 药物组合物的第二组分是5-羟色胺再摄取抑制剂，去甲肾上腺素再摄取抑制剂，5-HT2A调节剂或多巴胺再摄取抑制剂。 在某些实施方案中，药物组合物包含依佐匹克。 在优选的实施方案中，药物组合物包含依佐匹克和氟西汀。 本发明还涉及一种治疗睡眠异常，治疗失眠，治疗抑郁症，增强抗抑郁药治疗，引发剂量保留作用，减少抑郁症复发，改善抗抑郁治疗疗效或提高抗抑郁治疗耐受性的方法，包括 向有需要的患者共同施用GABA受体调节化合物; 和SRI，NRI，5-HT2A调节剂或DRI。

公开(公告)号：US07714023B2

公开(公告)日：2010-05-11

申请号：US11060067

申请日：2005-02-17

Applicant: Timothy J. Barberich

Inventor： Timothy J. Barberich

IPC: A01N43/08 ,  A61K31/34 ,  A61K31/40 ,  A01N43/38 ,  A01N33/02 ,  A61K31/135 ,  C07D307/87

CPC classification number: A61K31/343

Abstract: Methods for prophylaxis of or treating or preventing migraine or migraine headaches, or other headache disorders include administering to a subject in need of treatment a therapeutically effective amount of citalopram, escitalopram, or a racemic or optically pure citalopram metabolite, or pharmaceutically acceptable salts, solvates, polymorphs, or hydrates thereof.

Abstract translation: 用于预防或治疗或预防偏头痛或偏头痛或其他头痛障碍的方法包括向需要治疗的受试者施用治疗有效量的西酞普兰，依他普仑或外消旋或光学纯的西酞普兰代谢物或其药学上可接受的盐溶剂化物 ，多晶型物或其水合物。

公开(公告)号：US20080125461A1

公开(公告)日：2008-05-29

申请号：US11547687

申请日：2005-04-05

Applicant: Timothy J. Barberich

Inventor： Timothy J. Barberich

IPC: A61K31/47 ,  A61K31/135 ,  A61K31/40 ,  A61P11/06

CPC classification number: A61K31/167 ,  A61K31/404 ,  A61K31/47 ,  A61K45/06 ,  C07C2601/16 ,  A61K2300/00

Abstract: This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using stereomerically pure (R,R)-formoterol in combination with other pharmacological agents such as leukotriene inhibitors and neurokinin receptor antagonists. Pharmaceutical compositions comprising (R,R)-formoterol and other pharmacological agents are also disclosed.

Abstract translation: 本发明涉及使用立体纯的（R，R） - 福莫特罗与其他药理学试剂如白三烯抑制剂和神经激肽受体拮抗剂组合治疗，预防和治疗各种肺部疾病或病症的方法。 还公开了包含（R，R） - 福莫特罗和其他药理学试剂的药物组合物。

公开(公告)号：US06835740B2

公开(公告)日：2004-12-28

申请号：US10075617

申请日：2002-02-15

Applicant: Paul D. Rubin ,  Timothy J. Barberich

Inventor： Paul D. Rubin ,  Timothy J. Barberich

IPC: A61R31445

CPC classification number: A61K31/445 ,  A61K31/4468

Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia, nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.

Abstract translation: 使用（+）诺西沙必利或其药学上可接受的盐预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，神经性，肠易激综合征，尿失禁，心动过缓，缓慢性心律失常，晕厥，其他障碍或其症状 ，基本上不含（ - ）立体异构体。

公开(公告)号：US06649183B2

公开(公告)日：2003-11-18

申请号：US09985099

申请日：2001-11-01

Applicant: Paul D. Rubin ,  Timothy J. Barberich

Inventor： Paul D. Rubin ,  Timothy J. Barberich

IPC: A61F1300

CPC classification number: A61K31/415 ,  A61K31/4178 ,  A61K31/00 ,  A61K2300/00

Abstract: Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.

公开(公告)号：US06559165B1

公开(公告)日：2003-05-06

申请号：US09722391

申请日：2000-11-28

Applicant: Paul D. Rubin ,  Timothy J. Barberich

Inventor： Paul D. Rubin ,  Timothy J. Barberich

IPC: A61K31445

CPC classification number: A61K31/445 ,  A61K31/4468

Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

Abstract translation: 使用（ - ）诺西沙必利或其药学上可接受的盐的预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，肠易激综合征，尿失禁，心动过缓，缓慢性心律失常，晕厥，其他障碍或其症状的方法， 基本上不含（+）立体异构体。

公开(公告)号：US06465469B1

公开(公告)日：2002-10-15

申请号：US09545475

申请日：2000-04-07

Applicant: Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K31525

CPC classification number: A61K31/496 ,  C07D249/12

Abstract: The S-isomer of the hydroxy metabolite of nefazodone, S-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. S-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.

Abstract translation: 奈法唑酮的羟基代谢物的S-异构体S-羟基芬那唑酮是抑制剂的有效治疗剂，其不会引起与奈法唑酮相关的不良反应。 S-羟基诺法唑酮也可用于治疗偏头痛，恐慌症，创伤后应激障碍和睡眠障碍。